Forward Equity Partners

Global Healthcare Private Equity Firm

About us

Cross-border private equity firm focused on Healthcare / Life Science investments globally


Formerly Medivate Partners, Forward Equity Partners is a leading PE firm in Korea with proven track record in cross-border/healthcare transactions
What we do

We invest in innovative companies that provide essential technology and infrastructure for human health advancement

PEOPLE

Proven industry veterans

CEO & Managing PaRtner

Paul H. Kim

Advisory Partner

Alain Schreiber

ManAging partner

Hong Jun Park

Venture Partner

Alain Rolland

OUR LATEST UPDATEs

CHA Vaccine Institute

Convertible Note investment, Sep 2024

RIVA THERAPEUTICS

Series A-1 investment, Jun 2023

CMG Pharmaceuticals

Convertible Note investment, Mar 2023

SCAI THERAPEUTICS

Series B investment, Jul 2021

Media Center


Matica Bio Aims to Surpass China’s Wuxi and Dominate the Global Cell & Gene Therapy CDMO Market

Sep 2025


Matica Bio’s ‘Paul Kim Effect’: Partnerships with Innovative Companies Validate Viral Vector Platform Technology

Sep 2025


CHA Biotech’s Matica Biotechnology Expands Global CGT CDMO Network, Driving Revenue Growth

Jun 2024


CHA Biotech’s U.S. Subsidiary Matica Biotechnology Appoints Paul Kim as CEO

Feb 2024

Numbers

Our growing figures

Current Investments
Exits in healthcare
0
PorTFOLIO

Featured Portfolio

COGNATE BIOSERVICES

Feb 2021, Acquired by Charles River Laboratories

GENOPIS, Inc.

Mar 2021, Acquired by Wacker Chemie AG

WCCT GLOBAL

Feb 2021, Acquired by Altasciences/Novo Holdings

SILLAJEN

Dec 2017, Exited in public market

Partnering with global entrepreneurs